A recent study found that semaglutide treatment significantly reduced ALT levels in NAFLD at-risk patients, and histological data are awaited from an ongoing phase 2 trial of semaglutide in biopsy-proven NASH76. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.